Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA6 | P23280 | 4/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA4 | P22748 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetamide SCHEMBL6065998 | 0.98 | CYP2C19 (0.46) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL2412348 | 0.95 | CYP2C19 (0.52) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL15231954 | 0.93 | CYP2C19 (0.50) | CYP2C19CYP2C9CA12CA6CA7 | |
| Acetamide SCHEMBL11164476 | 0.88 | CA12 (0.59) | CYP2C19CYP2C9CA12CA6CA7 | |
| SCHEMBL8599501 | 0.83 | CYP2C9 (0.56) | CYP2C19CYP2C9CA12CA6CA7 | |
| Acetone SCHEMBL27949420 | 0.80 | CA12 (0.62) | CYP2C19CYP2C9CA12CA6CA7 | |
| Acetamide SCHEMBL28511193 | 0.79 | PAOX (0.39) | CYP2C19CYP2C9CA12CA6CA7 | |
| Acetic Acid SCHEMBL3657736 | 0.78 | CA12 (0.59) | CYP2C19CYP2C9CA12CA6CA7 | |
| Acetic Acid SCHEMBL18288 | 0.78 | CA12 (0.59) | CYP2C19CYP2C9CA12CA6CA7 | |
| Acetic Acid SCHEMBL9100273 | 0.78 | CA12 (0.59) | CYP2C19CYP2C9CA12CA6CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118317796-A | EGFRvIII targeting compounds and uses thereof | 加拿大国立研究院 | 2024-07-09 | — | — | CN | claimed |
| CN-117603148-A | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2024-02-27 | — | — | CN | claimed |
| WO-2011119340-A1 | SMART CONTRAST AGENT AND METHOD FOR DETECTING TRANSITION METAL IONS AND TREATING RELATED DISORDERS | I.S.T. CORPORATION (JP) | 2011-09-29 | — | — | WO | claimed |
| US-20100227794-A1 | SMART CONTRAST AGENT AND METHOD FOR DETECTING TRANSITION METAL IONS AND TREATING RELATED DISORDERS | I.S.T. CORPORATION (JP) | 2010-09-09 | — | — | US | claimed |
| US-20040259811-A1 | Chemotherapy method using x-rays | NANODYNAMICS INC. | 2004-12-23 | — | — | US | claimed |
| CN-118317796-A | EGFRvIII targeting compounds and uses thereof | 加拿大国立研究院 | 2024-07-09 | — | — | CN | disclosed |
| CN-117794585-A | Radioimmunoconjugates and checkpoint inhibitor combination therapies | 融合制药公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117603148-A | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2024-02-27 | — | — | CN | disclosed |
| CN-117482261-A | Combination therapy of radioimmunoconjugates and checkpoint inhibitors | 融合制药公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117321081-A | Immunoconjugates for targeted radioisotope therapy | 雅博得乐医疗公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-111263747-B | Pharmacokinetic enhancement of difunctional chelates and uses thereof | 探针技术开发及商业化中心 | 2023-10-27 | — | — | CN | disclosed |
| EP-2820070-B1 | POLYMERIC NANOPARTICLES USEFUL IN THERANOSTICS | GOVERNING COUNCIL UNIV TORONTO (CA) | 2023-07-26 | — | — | EP | disclosed |
| US-20090311182-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-17 | — | — | US | disclosed |
| US-20090155181-A1 | Compositions Useful for Reducing Toxicity Associated with Gadolinium-based Contrast Agents | VERROW PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2009004357-A2 | A METHOD OF HYPERPOLARISING A MAGNETIC RESONANCE AGENT | UNIVERSITY COLLEGE LONDON (GB) | 2009-01-08 | — | — | WO | disclosed |
| US-20080159959-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2007124131-A2 | HYBRID NANOMATERIALS AS MULTIMODAL IMAGING CONTRAST AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1737428-A1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | University of Utah Research Foundation (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060025713-A1 | Magnetic particle-based therapy | ENERGY, UNITED STATES DEPARTMENT OF | 2006-02-02 | — | — | US | disclosed |
| WO-2005097073-A1 | MACROMOLECULAR DELIVERY SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259811-A1 | Chemotherapy method using x-rays | XPOT, XPA, XPO4 | CYP2C19 3232/4885CYP2C9 3547/4885CA12 1142/4885 |
| US-20100227794-A1 | SMART CONTRAST AGENT AND METHOD FOR DETECTING TRANSITION METAL IONS AND TREATING RELATED DISORDERS | PRNP, IAPP, APP | CYP2C19 4759/4885CYP2C9 4783/4885CA12 873/4885 |
| US-20090311182-A1 | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases | MMP1, MSR1, CD68 | CYP2C19 4862/4885CYP2C9 4660/4885CA12 1456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.